Status:
RECRUITING
Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
Lead Sponsor:
Consorci Sanitari de Terrassa
Collaborating Sponsors:
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Institut Català de la Salut
Conditions:
COVID19
Influenza Vaccination
Eligibility:
All Genders
Brief Summary
Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since ...
Detailed Description
The number COVID cases would be related to hospital admissions. Among hospital admissions, the number of previous treatments, the length of admission, the need or not of the Intensive Care Unit (ICU) ...
Eligibility Criteria
Inclusion
- Hospital Admissions at the Hospital of Terrassa from March 1, 2020 for any cause.
Exclusion
- None.
- For comparison of percentage of Influenza vaccination, ACEI and ARB vs general population, patients from outside the reference area of the Terrassa Health Consortium would be excluded.
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 24 2028
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT04367883
Start Date
March 1 2020
End Date
February 24 2028
Last Update
March 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Terrassa
Terrassa, Barcelona, Spain, 08227